Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded Tonix Pharmaceuticals from “hold” to “sell.” Analyst opinions remain mixed: MarketBeat reports a consensus “buy” rating and an average price target of $22.33.
• Shares opened at $3.01 and were down 7.1%; they have traded between $2.90 and $20.56 over the past 12 months.
• Tonix reported a quarterly loss of $2.89 per share, missing the $2.39 loss analysts expected, while revenue of $17.23 million topped estimates of $16.32 million.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Saturday, Wall Street Zen reports.

A number of other analysts also recently weighed in on TNXP. Raymond James Financial reiterated a "strong-buy" rating on shares of Tonix Pharmaceuticals in a research report on Tuesday, October 20th. Weiss Ratings restated a "sell (e+)" rating on shares of Tonix Pharmaceuticals in a report on Monday, October 26th. Finally, Canaccord Genuity Group assumed coverage on shares of Tonix Pharmaceuticals in a research note on Monday, October 26th. They issued a "buy" rating and a $18.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $22.33.

Tonix Pharmaceuticals Stock Down 7.1%

Shares of TNXP opened at $3.01 on Friday. The stock's fifty day simple moving average is $7.72 and its 200-day simple moving average is $11.85. The firm has a market capitalization of $58.48 million, a PE ratio of -0.25 and a beta of 1.90. Tonix Pharmaceuticals has a 12-month low of $2.90 and a 12-month high of $20.56.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($2.89) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.39) by ($0.50). The business had revenue of $17.23 million during the quarter, compared to the consensus estimate of $16.32 million. Tonix Pharmaceuticals had a negative net margin of 420.45% and a negative return on equity of 80.97%. Analysts anticipate that Tonix Pharmaceuticals will post -10.42 EPS for the current year.

Insider Transactions at Tonix Pharmaceuticals

In other Tonix Pharmaceuticals news, CEO Seth Lederman purchased 2,000 shares of the stock in a transaction on Thursday, August 27th. The stock was bought at an average cost of $13.79 per share, for a total transaction of $27,580.00. Following the completion of the acquisition, the chief executive officer directly owned 11,005 shares of the company's stock, valued at $151,758.95. The trade was a 22.21% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders bought 8,000 shares of company stock valued at $60,430 over the last ninety days. 2.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Tonix Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Global Retirement Partners LLC acquired a new position in shares of Tonix Pharmaceuticals in the 3rd quarter valued at approximately $28,000. Steward Partners Investment Advisory LLC bought a new stake in Tonix Pharmaceuticals during the 3rd quarter worth approximately $39,000. Integrated Wealth Concepts LLC acquired a new stake in Tonix Pharmaceuticals during the 2nd quarter worth approximately $92,000. Empowered Funds LLC acquired a new stake in Tonix Pharmaceuticals during the 3rd quarter worth approximately $192,000. Finally, Great Lakes Advisors LLC bought a new position in Tonix Pharmaceuticals in the second quarter valued at approximately $303,000. Institutional investors own 82.26% of the company's stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp. is a U.S.-based biopharmaceutical company that develops and commercializes medicines for central nervous system disorders and pursues research programs in immunology, rare diseases and infectious diseases. Its product Tonmya (cyclobenzaprine hydrochloride sublingual tablets) received U.S. Food and Drug Administration approval in 2025 for the treatment of fibromyalgia in adults. The company also has a development pipeline that includes drug candidates and vaccine programs, including research targeting smallpox and mpox.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.